Is retatrutide safe?
Safety is the most important question about any compound that is still in testing. This guide sticks to what the published trials actually reported, is clear about what is not yet known, and explains why the source of the material matters as much as the molecule.
On this page
Is retatrutide safe?
The honest answer is that it is still being studied. Retatrutide has gone through Phase 2 and much of Phase 3 testing, and in those trials its safety profile has looked broadly similar to other drugs in the GLP-1 family. But because the full programme is not finished and it is not approved, no one can responsibly claim a complete long-term safety record. Anything stronger than that gets ahead of the evidence.
What side effects appeared in trials?
The most commonly reported side effects in retatrutide trials were gut related. These included nausea, diarrhoea, constipation and vomiting, and were generally described as mild to moderate and more likely when a dose was increased. This pattern is typical for the GLP-1 drug family, which acts on the gut and appetite system. Our guide on managing retatrutide and GLP-1 side effects covers what trials reported in more detail, and a separate guide looks at the specific question of muscle loss.
Summary of side effects reported in published clinical trials. Not medical advice and not a claim about any individual.
What is not known yet?
Two things are still open. First, long-term effects over many years are not established, because the compound is new and the trials are still reading out. Second, retatrutide has not been approved, so it has not passed the final regulatory safety review that approved medicines have. Until that happens, the safety picture is a snapshot from trials rather than a settled conclusion. For where approval stands, see is retatrutide FDA approved.
Why the source of the material matters
For anything sold for research, quality is not guaranteed by the name on the label. Purity, correct identity and low contamination are what separate well-made material from poorly-sourced material, and the only way to check is a lot-specific Certificate of Analysis from a testing laboratory. A CoA reports the measured purity and net peptide content for that exact batch. Our guide on how to read a CoA explains what to look for, and how to spot poorly-sourced peptides covers the warning signs.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
- Retatrutide (LY3437943) Phase 3 TRIUMPH program. ClinicalTrials.gov. Trial records.
Frequently asked questions
Is retatrutide safe to use?
It is still in trials, so its long-term safety is not fully established. Trial side effects were mostly mild to moderate and gut related. It is not an approved medicine.
What are the most common retatrutide side effects?
Gut-related effects such as nausea, diarrhoea, constipation and vomiting were the most commonly reported in trials, usually mild to moderate.
Does retatrutide have long-term safety data?
Not yet. The compound is new and Phase 3 trials are still reading out, so long-term effects over many years are not established.
Is research-grade retatrutide the same as a prescription?
No. Material sold for research use is not tested or approved for human use, and its quality depends entirely on lot-specific third-party testing.